Zocere, Inc. is a New Mexico-based biotech company that is developing novel therapeutics for neurological diseases, including stroke, and offering services to other entities developing stroke-related diagnostics and treatments. We have licensed patented technology for a derivative of the brain-specific  STEP protein, tyrosine phosphatase, developed at the University of New Mexico. This technology is the foundation for a novel, generation next therapeutic treatment of stroke that shows promise of becoming the first injectable neuroprotectant drug in the market.

Leadership Team


Wayne Laslie President and CEO

Wayne Laslie has more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets.
He has served in positions of clinical development, business development and commercial development, along with sales, marketing and operations. Prior to joining Zocere, Inc., Laslie held increasingly responsible positions at Pfizer and predecessor companies of Sanofi-Aventis (now Sanofi); was executive vice president at Otsuka America Pharmaceuticals, and most recently he was the chief operating officer at Myriad Pharmaceuticals and Myrexis. Laslie is a former board member of the National Pharmaceutical Council and a past member of the University of Maryland’s Chancellor’s Advisory Committee


Kenton H. Zavitz, PhD Chief Scientific Officer

Kenton H. Zavitz, PhD, has more than 15 years of biotechnology and pharmaceutical experience, ranging from drug discovery and clinical development to pre-commercialization.
In 1998, Zavitz joined Myriad Genetics, Inc. in Salt Lake City and worked for its subsidiary Myriad Pharmaceuticals, Inc. (later spun out as an independent public company and renamed Myrexis, Inc.). During his tenure with Myriad/Myrexis, Zavitz served as senior director of Clinical Affairs, chief scientist of the tarenflurbil clinical development program (an investigational drug for treating Alzheimer’s disease, developed through Phase 3), director of Neurodegeneration Therapeutics Discovery, director of Strategic In-licensing and Scientific Evaluation, and head of Drug Target Discovery and Validation. He has worked on the development of new drug products in various therapeutic areas, including Alzheimer’s disease, acute pain, HIV, oncology, and inflammatory diseases.

Meet Zocere’s Board of Directors
“We’ve coupled a strong leadership team and board to accelerate the development and commercialization pathways of our stroke therapeutics with a tight financial strategy to leverage investment capital.” Wayne Laslie, CEO Zocere, Inc.

asa Proud supporter of the American Stroke Association